Format

Send to

Choose Destination
Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1630-7. doi: 10.1007/s00259-016-3347-z. Epub 2016 Feb 24.

FDG-PET/ceCT is useful to predict recurrence of Pseudomyxoma peritonei.

Author information

1
Nuclear Medicine and PET Unit, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite, France. julien.dubreuil@chu-lyon.fr.
2
Equipe Mixte de Recherche 3738, Université Claude Bernard Lyon 1, Lyon, France. julien.dubreuil@chu-lyon.fr.
3
Nuclear Medicine Department, Groupement Hospitalier Est, Hospices Civils de Lyon 59, boulevard Pinel, 69677, Bron, France.
4
Biophysique - Faculté Charles Mérieux Lyon, Lyon, France.
5
Equipe Mixte de Recherche 3738, Université Claude Bernard Lyon 1, Lyon, France.
6
Radiology Department, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite, France.
7
Gynaecology Department, Groupement Hospitalier Est, Hospices Civils de Lyon, 59, boulevard Pinel, 69677, Bron, France.
8
General and oncologic surgery Department, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite, France.
9
Pathology Department, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite, France.
10
Lyon 1 University, 43 Boulevard du 11 Novembre 1918, 69100, Villeurbanne, France.
11
Nuclear Medicine and PET Unit, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, 165 Chemin du Grand Revoyet, 69495, Pierre-Bénite, France.

Abstract

PURPOSE:

Pseudomyxoma peritonei (PMP) is a rare peritoneal neoplasm originating from appendicular tumours. There is no consolidated data available in the literature about the precise role of [(18)F] fluorodesoxy-D-glucose Positron Emission Tomography / contrast enhanced Computed Tomography (FDG-PET/ceCT). The aim of this study was to evaluate the correlation between preoperative FDG-PET/ceCT (qualitative and semi-quantitative assessment) and progression free survival (PFS) of patients treated for PMP.

METHODS:

All patients scheduled for PMP treatment by cytoreductive unicentric surgery, intraperitoneal chemotherapy (HIPEC), and who underwent a FDG-PET/ceCT between February 2008 and January 2014, were included. No previous treatment was performed (except biopsy or appendectomy). FDG-PET/ceCT was interpreted by two nuclear physicians in consensus. Positive FDG-PET/ceCT scans were further labelled in diffuse disease and poly/mono focal disease. SUVmax was measured based on post-operative reports. The Peritoneal Cancer Index (PCI) and Completeness of CytoReduction Score (CCR) were assessed after surgery.

RESULTS:

Fifty-six patients were included in this study, with a mean age of 56-years-old and a mean follow-up of 29.3 months. SUVmax, with a cut-off at 2.02, was predictive for the PFS on multivariate analysis. No differences were observed between diffuse disease and focal disease on PFS for progression free survival, PCI, and SUVmax (p = 0.1). Post-operative CCR was not significantly correlated with SUVmax or FDG-PET/ceCT qualitative assessment.

CONCLUSION:

SUVmax on preoperative FDG-PET/ceCT was an independent predictive factor for PFS in PMP. Further studies are needed to explore if FDG-PET/ceCT could potentially predict post-operative CCR.

KEYWORDS:

FDG-PET/ceCT; Intraperitoneal chemotherapy; Prognosis; Pseudomyxoma peritonei; Recurrence

PMID:
26907364
DOI:
10.1007/s00259-016-3347-z
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center